NECLIFE Stock Overview
Manufactures and sells pharmaceutical products in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Nectar Lifesciences Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹43.54 |
| 52 Week High | ₹56.50 |
| 52 Week Low | ₹26.15 |
| Beta | 1.11 |
| 1 Month Change | 21.96% |
| 3 Month Change | -1.23% |
| 1 Year Change | 37.13% |
| 3 Year Change | 62.77% |
| 5 Year Change | 244.19% |
| Change since IPO | 67.40% |
Recent News & Updates
Recent updates
Nectar Lifesciences (NSE:NECLIFE) Seems To Use Debt Quite Sensibly
Dec 15
Revenues Working Against Nectar Lifesciences Limited's (NSE:NECLIFE) Share Price Following 26% Dive
Oct 11Nectar Lifesciences Limited (NSE:NECLIFE) Shares Fly 31% But Investors Aren't Buying For Growth
Aug 22Here's Why Nectar Lifesciences (NSE:NECLIFE) Has A Meaningful Debt Burden
Jul 27Nectar Lifesciences Limited (NSE:NECLIFE) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Feb 19Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Dec 22Nectar Lifesciences (NSE:NECLIFE) Has Debt But No Earnings; Should You Worry?
Jun 16Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jun 21Nectar Lifesciences (NSE:NECLIFE) Takes On Some Risk With Its Use Of Debt
Jul 29Is Nectar Lifesciences Limited (NSE:NECLIFE) A Risky Dividend Stock?
Feb 25Nectar Lifesciences (NSE:NECLIFE) Has A Somewhat Strained Balance Sheet
Jan 21Zooming in on NSE:NECLIFE's 0.3% Dividend Yield
Nov 02Does Nectar Lifesciences (NSE:NECLIFE) Have A Healthy Balance Sheet?
Sep 07
If You Had Bought Nectar Lifesciences (NSE:NECLIFE) Stock A Year Ago, You Could Pocket A 47% Gain Today
Aug 09The Nectar Lifesciences (NSE:NECLIFE) Share Price Has Gained 47% And Shareholders Are Hoping For More
Aug 09What You Can Learn From Nectar Lifesciences Limited's (NSE:NECLIFE) P/E
Jul 13Shareholder Returns
| NECLIFE | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 23.9% | -1.0% | -0.9% |
| 1Y | 37.1% | 39.2% | 22.5% |
Return vs Industry: NECLIFE underperformed the Indian Pharmaceuticals industry which returned 39.2% over the past year.
Return vs Market: NECLIFE exceeded the Indian Market which returned 22.5% over the past year.
Price Volatility
| NECLIFE volatility | |
|---|---|
| NECLIFE Average Weekly Movement | 6.5% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: NECLIFE has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: NECLIFE's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 1,686 | Amit Chadah | www.neclife.com |
Nectar Lifesciences Limited manufactures and sells pharmaceutical products in India and internationally. The company’s active pharmaceutical ingredients and intermediates comprise cefixime, cefuroxime axetil amorphous, cefuroxime axetil crystalline, cefotaxime sodium, ceftriaxone sodium, cefixime trihydrate, cefuroxime axetil, cefpodoxime proxetil and sterile, cefprozil, cefdinir, cefuroxime sodium, cefazolin sodium, ceftazidime pentahydrate, and cefepime +Arginine. It also offers contract manufacturing for finished dosage forms, such as tablets, capsules, dry powder oral suspensions, and granules and injectable for cephalosporins.
Nectar Lifesciences Limited Fundamentals Summary
| NECLIFE fundamental statistics | |
|---|---|
| Market cap | ₹9.57b |
| Earnings (TTM) | ₹107.27m |
| Revenue (TTM) | ₹16.79b |
91.0x
P/E Ratio0.6x
P/S RatioIs NECLIFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NECLIFE income statement (TTM) | |
|---|---|
| Revenue | ₹16.79b |
| Cost of Revenue | ₹11.69b |
| Gross Profit | ₹5.11b |
| Other Expenses | ₹5.00b |
| Earnings | ₹107.27m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.48 |
| Gross Margin | 30.40% |
| Net Profit Margin | 0.64% |
| Debt/Equity Ratio | 58.4% |
How did NECLIFE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 13:31 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nectar Lifesciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Naveed MD. | FirstCall Research |